Wednesday, July 8, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “advanced-solid-tumors” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 61
Total indexed 20,548
Sponsors 1,769

Quick answer

Showing 61 pipeline programs matching "advanced-solid-tumors" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

61 results for “advanced-solid-tumors” Back to intelligence hub

Search results

Page 1 of 3
  1. Apatinib

    The First People's Hospital of Lianyungang

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial
  2. BMS-986466

    Bristol-Myers Squibb

    Advanced Solid Tumors

    phase 2 small molecule terminated

    1 trial
  3. CTX-009 (ABL001)

    Compass Therapeutics

    P1b: Advanced Solid Tumors

    phase 2 small molecule terminated

    1 trial
  4. Daraxonrasib

    Revolution Medicines

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial
  5. EIK1004-001 (IMP1707-001)

    Eikon Therapeutics

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial
  6. EIK1005

    Eikon Therapeutics

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial
  7. Monalizumab

    MedImmune

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial
  8. PYX-201

    Pyxis Oncology

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial
  9. REGN7075

    Regeneron UK Limited

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial
  10. SKB103 for injection monotherapy

    Sichuan Provincial People's Hospital

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial
  11. Trastuzumab deruxtecan

    AstraZeneca

    Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast

    phase 2 small molecule active

    1 trial
  12. indibulin

    Alaunos Therapeutics

    Advanced Solid Tumors

    phase 2 small molecule active

    2 trials
  13. 2X-121 and dovitinib

    Allarity Therapeutics

    Advanced Solid Tumors

    phase 1 small molecule on hold

    1 trial
  14. ACR-2316

    Acrivon Therapeutics

    Specific Advanced Solid Tumors

    phase 1 small molecule active

    1 trial
  15. ADCT-601

    ADC Therapeutics SA

    Advanced Solid Tumors

    phase 1 small molecule terminated

    2 trials
  16. ADCT-901

    ADC Therapeutics SA

    Advanced Solid Tumors

    phase 1 small molecule completed

    1 trial
  17. AMT-676

    Multitude Therapeutics

    Advanced Solid Tumors

    phase 1 small molecule active

    1 trial
  18. Alisertib

    Takeda

    Advanced Solid Tumors

    phase 1 small molecule completed

    7 trials
  19. Anti-CDH17 CAR-T cells infusion

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    CDH17-positive Advanced Solid Tumors

    phase 1 mab active

    1 trial
  20. Atu027

    Silence Therapeutics plc

    Advanced Solid Tumors

    phase 1 small molecule completed

    1 trial
  21. BAY2965501

    Bayer HealthCare AG

    Advanced Solid Tumors

    phase 1 small molecule active

    1 trial
  22. BC006

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Advanced Solid Tumors (Including GCTTS)

    phase 1 small molecule active

    1 trial
  23. BEL-X-HG

    Taiwan Liposome Company

    Advanced Solid Tumors

    phase 1 small molecule terminated

    1 trial
  24. BG-C477

    BEONE MEDICINES AUS PTY LTD

    Advanced Solid Tumors

    phase 1 small molecule active

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.